Peyronie’s disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peyronie’s disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Vibrio Alginolyticus Collagenase and Alprostadil for Patients with Peyronie’s Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vibrio-alginolyticus-collagenase-and-alprostadil-for-patients-with-peyronies-disease/ Wed, 29 Apr 2026 15:02:36 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vibrio-alginolyticus-collagenase-and-alprostadil-for-patients-with-peyronies-disease/ This clinical trial is focused on studying a condition known as Peyronie’s Disease, which affects the penis and can cause it to curve abnormally. The study will use a treatment called Vibrio alginolyticus collagenase, which is a type of enzyme that breaks down proteins. This enzyme will be injected directly into the plaque, which is the area causing the curvature. The study will also involve the use of Alprostadil, a medication that helps induce an erection, to measure changes in the curvature of the penis.

The purpose of the study is to evaluate the safety and effectiveness of the enzyme treatment. The study will be conducted in two phases. In the first phase, different doses of the enzyme will be tested to find the safest and most effective dose. In the second phase, this dose will be used to see how well it improves the curvature of the penis. Participants will receive injections of the enzyme and will be monitored for any changes in their condition, as well as any side effects they might experience.

Throughout the study, participants will have regular check-ups to assess the impact of the treatment on their condition. The study aims to provide a better understanding of how this enzyme can help treat Peyronie’s Disease and improve the quality of life for those affected by it. The study will continue until the estimated end date in 2027.

]]> Study on the Use of FAPI-PET/CT and FDG-PET/CT Scans for Detecting Active Fibroblasts and Inflammation in Patients with Acute Phase Peyronie’s Disease https://clinicaltrials.eu/trial/study-on-the-use-of-fapi-pet-ct-and-fdg-pet-ct-scans-for-detecting-active-fibroblasts-and-inflammation-in-patients-with-acute-phase-peyronies-disease/ Wed, 29 Apr 2026 15:02:31 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-fapi-pet-ct-and-fdg-pet-ct-scans-for-detecting-active-fibroblasts-and-inflammation-in-patients-with-acute-phase-peyronies-disease/ This clinical trial is focused on studying Peyronie’s Disease, a condition that affects the penis and can cause painful erections and the development of a hard lump or nodule. The study aims to explore the use of two types of scans, FAPI-PET/CT and FDG-PET/CT, to detect active fibroblast tissue and inflammation in patients who are in the early stages of this disease.

The treatment being investigated involves the use of a special solution for injection called [68Ga]FAPI-46. This solution is designed to help highlight areas of active fibroblast activity and inflammation during the scans. The purpose of the study is to determine if these scans can effectively identify these active areas in the penis, which could help in understanding and diagnosing the condition better.

Participants in the study will undergo these scans to see if the FAPI-PET/CT and FDG-PET/CT can detect the active fibroblasts or inflammation. The study will take place over a period, and the results will help researchers understand the potential benefits of using these scans in diagnosing Peyronie’s Disease during its acute phase.

]]>